Bristol-Myers Squibb Co to Hold Investor Webcast to Discuss ASH Highlights Transcript
Hi, everybody. My name is John Elicker. I lead Corporate Affairs and Investor Relations for Bristol. A lot of familiar faces in the room, but also a lot of new faces.
It's a very exciting time for us to be come together for the first time at a very important medical meeting. And overall, more broadly, it's a very exciting time for the company. And as we reflect back over the course of the year, you don't get to an exciting time like this without being on a journey. And no doubt, we've been on a journey since a little not quite a year ago, and many of you in this room have been on that journey with us. But when we look back and think about the last 11.5 months or so, pretty much everything has gone at or ahead of expectations.
If you look at the business performance of both Bristol-Myers Squibb and Celgene over the course of 2019, very strong. Good, strong underlying fundamentals, which positions the company very well for the future. If you look at a lot of the discussion about Revlimid. We had 2 IPRs go in our favor,
| Access to All Earning Calls and Stock Analysis | |
| 30-Year Financial on one screen | |
| All-in-one Stock Screener with unlimited filters | |
| Customizable Stock Dashboard | |
| Real Time Insider Trading Transactions | |
| 8,000+ Institutional investors’ 13F holdings | |
| Powerful Excel Add-in and Google sheets Add-on | |
| All data downloadable | |
| Quick customer support | |
| And much more... |
Trustpilot
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
